Immunology & Cancer Immunotherapy (ICI)

项目摘要/摘要：免疫学和癌症免疫治疗（ICI） 免疫学和癌症免疫治疗（ICI）计划的总体目标是团结基础免疫学和癌症免疫治疗的努力。 和临床免疫学家探索免疫系统对癌症发展和进展的影响， 开发利用免疫力治疗癌症的新策略，并进行临床试验， 治疗和方法，以改善患者的结果和增加总生存期。有二十一 成员来自六个不同的学术部门和两个专业学校。当前的重点和 ICI科学家的计划主要集中在三个主题上：免疫调节，免疫效应器， 机制和转化免疫疗法。免疫治疗方法主要集中在过继免疫治疗。 T细胞治疗、疫苗接种和免疫调节阻断。虽然基础研究是一个关键的焦点，许多教师 成员积极参与从实验室到临床的转化研究。其他成员是临床医生 （血液学家，肿瘤学家或肿瘤外科医生）积极参与临床研究和临床 审判该计划将建立和经验丰富的临床试验专家与NCI资助的癌症免疫学家联合起来， 设计，执行和完成达特茅斯发起的肾细胞癌，黑色素瘤， 胶质母细胞瘤、结肠直肠癌、多发性骨髓瘤和造血干细胞移植。有 ICI成员之间围绕免疫生物学共同感兴趣的领域开展广泛合作， 联合出版物和资助赠款证明了这一点。该计划的主要贡献 NCCC的使命是促进对肿瘤微环境的新认识， 白细胞、新型蛋白质和细胞疗法的发展、达特茅斯的翻译 研究者的想法纳入临床试验，以及这些试验的患者增加。NCCC已经做出了实质性的 致力于提高ICI计划的研究和临床翻译的深度和广度， 支持共享资源，为新的试点赠款提供财政奖励，并战略性地招聘新的 investigators.在报告所述期间发表了280多篇与癌症有关的文章，其中46篇 (16%）出现在高影响力的期刊上。计划内出版物（43=15%）涉及我们的22个中的19个 方案间出版物（66份=24%）涉及15名成员。2004 - 2005两年期赠款供资总额 该计划目前为640万美元，其中550万美元是同行评审，220万美元来自NCI。

Project Summary/Abstract: Immunology and Cancer Immunotherapy (ICI) The overall goal of the Immunology and Cancer Immunotherapy (ICI) Program is to unite the efforts of basic and clinical immunologists to explore the immune system's impact on cancer development and progression, to develop novel strategies that use immunity to treat cancer, and to conduct clinical trials to test novel therapeutics and approaches to improve patient outcomes and increase overall survival. There are twenty-one members from six different academic departments and two professional schools. The current focus and initiatives of the ICI scientists are centered on three themes: Immune regulation, Immune effector mechanisms, and Translational immunotherapy. The immunotherapy approaches are focused on adoptive T cell therapy, vaccination, and immune regulation blockade. While basic research is a key focus, many faculty members actively are involved in translational bench-to-bedside research. Other members are clinicians (hematologists, oncologists or oncologic surgeons) who actively are involved in clinical research and clinical trials. This program joins established and experienced clinical trialists with NCI-funded cancer immunologists to design, execute, and complete Dartmouth-initiated immunotherapy trials in renal cell carcinoma, melanoma, glioblastoma, colorectal carcinoma, multiple myeloma and hematopoietic stem cell transplantation. There are extensive collaborations between ICI members around common areas of interest in immunobiology and immunotherapy, as evidenced by joint publications and funded grants. Major contributions of the program to the mission of the NCCC have been the facilitation of new insights into the tumor microenvironment and how this is affected by leukocytes, the development of novel protein and cell therapies, the translation of Dartmouth investigator ideas into clinical trials, and the accrual of patients to these trials. NCCC has made substantial commitment to improving the depth and breadth of research and clinical translation of the ICI program through support of shared resources, financial awards for new pilot grants, and strategic recruitment of new investigators. More than 280 cancer-related articles have been published over the reporting period, with 46 (16%) appearing in high impact journals. Intra-programmatic publications (43=15%) involved 19 of our 22 members, and inter-programmatic publications (66=24%) involved 15 members. Total grant funding for the program currently is $6.4M, of which $5.5M is peer-reviewed and $2.2M is from NCI.